Description

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. A study by StrategyHelix indicates that the global liquid biopsy market is expected to increase by US$ 6,579.5 million from 2022 to 2028, garnering a CAGR of 16.1% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for liquid biopsy. The global liquid biopsy market is segmented on the basis of therapy, application, biomarker type, technology, and region. Based on therapy, the global liquid biopsy market is categorized into oncology, noninvasive prenatal testing (NIPT), others (e.g. organ transplant). The NIPT segment captured the largest share of the market in 2021. On the basis of application, the global liquid biopsy market has been segmented into diagnosis, early detection/screening, monitoring, therapy guidance. The early detection/screening segment held the largest share of the global liquid biopsy market in 2021 and is anticipated to hold its share during the forecast period. By biomarker type, the global liquid biopsy market has been segmented into cell-free nucleic acids, circulating tumor cells, others. In 2021, the cell-free nucleic acids segment made up the largest share of revenue generated by the liquid biopsy market. Based upon technology, the global liquid biopsy market is categorized into next-generation sequencing (NGS), polymerase chain reaction (PCR), others. Among these, the next-generation sequencing (NGS) segment was accounted for the highest revenue generator in 2021. In terms of geography, the global liquid biopsy market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global liquid biopsy market is highly competitive. Top players covered in Global Liquid Biopsy Market Study are Adaptive Biotechnologies Corp., Agilent Technologies Inc., Amoy Diagnostics Co. Ltd., Becton Dickinson and Company, Berry Genomics Co. Ltd., BGI Group, Biocartis Group, Biocept Inc., Biodesix Inc., Biolidics Limited, Bio-Rad Laboratories Inc., Bio-Techne Corp., CareDx Inc., Danaher Corp., Eurofins Scientific, EXACT Sciences Corporation, Illumina Inc., Koninklijke Philips N.V., Merck KGaA, Myriad Genetics Inc., NeoGenomics Laboratories Inc., OncoCyte Corporation, Oxford Nanopore Technologies Limited, Pacific Biosciences of California Inc., Qiagen N.V., Roche Holding AG, Takara Bio Inc., Thermo Fisher Scientific Inc., VolitionRx Limited.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the liquid biopsy market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Therapy: oncology, noninvasive prenatal testing (NIPT), others (e.g. organ transplant)
Application: diagnosis, early detection/screening, monitoring, therapy guidance
Biomarker type: cell-free nucleic acids, circulating tumor cells, others
Technology: next-generation sequencing (NGS), polymerase chain reaction (PCR), others
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders

– Get a comprehensive picture of the global liquid biopsy market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Liquid biopsy market overview
Part 3. Market breakdown by therapy
– Oncology
– Noninvasive prenatal testing (NIPT)
– Others (e.g. organ transplant)
Part 4. Market breakdown by application
– Diagnosis
– Early detection/screening
– Monitoring
– Therapy guidance
Part 5. Market breakdown by biomarker type
– Cell-free nucleic acids
– Circulating tumor cells
– Others
Part 6. Market breakdown by technology
– Next-generation sequencing (NGS)
– Polymerase chain reaction (PCR)
– Others
Part 7. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 8. Key companies
– Adaptive Biotechnologies Corp.
– Agilent Technologies Inc.
– Amoy Diagnostics Co., Ltd.
– Becton, Dickinson and Company
– Berry Genomics Co., Ltd.
– BGI Group
– Biocartis Group
– Biocept, Inc.
– Biodesix, Inc.
– Biolidics Limited
– Bio-Rad Laboratories, Inc.
– Bio-Techne Corp.
– CareDx, Inc.
– Danaher Corp.
– Eurofins Scientific
– EXACT Sciences Corporation
– Illumina, Inc.
– Koninklijke Philips N.V.
– Merck KGaA
– Myriad Genetics, Inc.
– NeoGenomics Laboratories, Inc.
– OncoCyte Corporation
– Oxford Nanopore Technologies Limited
– Pacific Biosciences of California, Inc.
– Qiagen N.V.
– Roche Holding AG
– Takara Bio Inc.
– Thermo Fisher Scientific Inc.
– VolitionRx Limited
About StrategyHelix
Disclaimer